Peer-reviewed publication features positive results from multiple ascending dose (MAD) portion of Phase 1 MBX 2109 study in ...

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical ...